Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPMA's Biopharmaceutical Committee Gears Up Activities
September 6, 2010
- Novartis Licenses Rabies Vaccine to Kaketsuken
September 6, 2010
- Precedex Approved for Long-Term Administration of over 24 Hours
September 6, 2010
- Takara Bio Begins Clinical Research for TCR Gene Therapy
September 6, 2010
- Genzyme Licenses Synvisc to Teijin Pharma
September 6, 2010
- Denosumab Applied for Bone Metastases: Daiichi Sankyo
September 6, 2010
- Towa to Expand Production Capacity with New Plant
September 6, 2010
- JCMOA to Be Kicked Off in October
September 6, 2010
- Banyu Files an NDA for Daptomycin
September 6, 2010
- Perampanel Shows Efficacy for Refractory Partial Seizure in PIII: Eisai
September 6, 2010
- Diovan Becomes Best-Selling Drug in April-June: IMS Japan
September 6, 2010
- Homeopathy Has No Scientific Grounds: SCJ
September 6, 2010
- Doctors Hope for Entry of Major Pharmas into Generics Market: Survey
September 6, 2010
- IBD Market to Grow to US$5.6 Bil. in 2019: Datamonitor
September 6, 2010
- Kyowa Kirin Withdraws Application for KW-2246
September 6, 2010
- Questionnaires on Use of Generics to Be Reconsidered
September 6, 2010
- JPMA Calls For Reduction in Effective Corporate Tax Rate to Int'l Standard
September 6, 2010
- Average PMDA Staff Member Earns ¥7,223,000 per Year
September 6, 2010
- Kyowa Kirin Launches Nesp Inj. Plastic Syringe
September 6, 2010
- 3 Switch OTC Drugs Recommended for Approval
September 6, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…